Discovery of S-217622, a SARS-covid CL Protease Inhibitor Clinical Candidate

[joseph...@msn.com]

Discovery of S-217622, a Noncovalent Oral SARS-covid CL Protease Inhibitor Clinical Candidate

 

Protease Inhibitor and Clinical Candidate for SARS-covid

Tyndall et al

Abstract

"The coronavirus disease (COVID-19) pandemic has highlighted the ability to quickly react to the immense disease processes presented to the world. The orally available CL protease inhibitor S-217622 is currently progressing through clinical trials and its discovery from structure-based drug design, screening and optimization by Shionogi and Hokkaido University is presented

---------------

Discovery of S-217622, a Noncovalent Oral SARS-covid CL Protease Inhibitor Clinical Candidate